Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment

Dynamic contrast-enhanced ultrasonography (DCEUS) using the contrast agent Sonovue and vascular recognition imaging software is a novel technique that enables the detection of microvessels and quantitative assessment of solid tumor perfusion using raw linear data. Clinical trials have shown that DCE-US can be used to assess the anticancer efficacy of antiangiogenic treatment, for which conventional efficacy criteria based on size are unsuitable. Reduction in tumor vascularization can easily be detected in responders after 1–2 weeks and is correlated with progression-free survival and overall survival. DCE-US is supported by the French Cancer National Institut. This program is currently studying the technique in metastatic breast cancer, melanoma, colon cancer, gastrointestinal stromal tumor, and renal cell carcinoma, as well as in primary hepatocellular carcinoma, to establish the optimal perfusion parameters and timing for quantitative anticancer efficacy assessments.

[1]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.

[2]  G. Benea,et al.  Effect of Angiosonography to Monitor Response During Imatinib Treatment in Patients with Metastatic Gastrointestinal Stromal Tumors , 2005, Clinical Cancer Research.

[3]  Christian Greis,et al.  Technology overview: SonoVue (Bracco, Milan). , 2004, European radiology.

[4]  Science to practice: Will improved assessment of response to antiangiogenic therapies be achieved with contrast-enhanced gray-scale US? , 2006, Radiology.

[5]  P. Terrier,et al.  Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Linda Chami,et al.  To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. , 2006, European journal of cancer.

[7]  O. Bouché,et al.  Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales (GIST) , 2005 .

[8]  Chin-Shang Li,et al.  Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. , 2006, Radiology.

[9]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[10]  J. Soria,et al.  Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma , 2007, Clinical Cancer Research.

[11]  B. Escudier,et al.  Phase II trial of thalidomide in renal-cell carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Terrier,et al.  Dynamic contrast-enhanced Doppler ultrasound (DCE-US) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Opolon,et al.  Evaluation of Contrast-Enhanced Color Doppler Ultrasound for the Quantification of Angiogenesis In Vivo , 2001, Investigative radiology.

[15]  O. Bouché,et al.  Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales , 2005 .

[16]  L. Chami,et al.  Imagerie des mélanomes : performances de l’échographie sans et avec injection de produit de contraste pour le diagnostic et l’évaluation des traitements , 2007 .

[17]  D. Cosgrove,et al.  Angiogenesis imaging--ultrasound. , 2003, The British journal of radiology.

[18]  V. Lazar,et al.  Sorafenib (S) and dacarbazine (D) combination in patients (pts) with advanced malignant solid tumors: Phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US) , 2007 .

[19]  Linda Chami,et al.  Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. , 2006, AJR. American journal of roentgenology.

[20]  Gordon C Jayson,et al.  Molecular imaging of antiangiogenic agents. , 2005, The oncologist.